GlassScriptPhysician profile
Cristobal Goa
NPI 1528201993
$6,018.08
in general payments reported to CMS, 2019-2025
44 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $629 · 2021: $518 · 2022: $1,074 · 2023: $660 · 2024: $1,086 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $748.00 | 2022 | |
| Janssen Biotech, INC. | $494.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $467.21 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $333.17 | 2020-2025 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $333.00 | 2019 | |
| Amgen INC. | $311.86 | 2019-2025 | Repatha, Repatha |
| Glaxosmithkline, LLC. | $292.17 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $289.78 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $268.92 | 2022-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $198.94 | 2020-2024 | |
| Genzyme Corporation | $195.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $186.31 | 2019-2024 | Opsumit, Uptravi |
| Boston Scientific Corporation | $180.28 | 2019-2025 | Watchman Access System |
| Abbott Laboratories | $159.25 | 2021-2023 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.52 | 2019-2025 | Jardiance |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristobal Goa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.